Page 2440 - Williams Hematology ( PDFDrive )

2411
2410 Index Index 2411

in monocytes, 1046, 1052, 1052f, 1054, CD23 CD38, 68, 1141, 1144t, 1531t, 1532
1056, 1095, 1097 in chronic lymphocytic leukemia, 1531, CD39, 1144t, 1834, 1885–1886
CD15 1532t, 1542 CD39 (ecto-ATP/Dase-1/CD39), 1967, 1968,
in acute lymphoblastic leukemia, in mantle cell lymphoma, 1593 1969f, 1971, 1972f
1512 in Waldenström macroglobulinemia, 1785, CD40
in acute myelogenous leukemia, 1380t, 1791 atherosclerosis and, 2288
1383 CD24, 1856 in dendritic cells, 309
in Hodgkin lymphoma, 1599, 1609, 1610 CD25 (IL-2Rα), 1700 in heavy-chain class switching, 1168
leukemoid reaction and, 986 CD25 deficiency, 1223 in Hodgkin lymphoma, 1599, 1607
CD16. See Fcγ receptor III (FcγRIII, CD16) CD25-targeted therapy. See Denileukin diftitox in inflammatory response, 1978
CD16/CD18, 1627 CD26, 1143, 1144t, 1682 mutations, autosomal recessive hyper-IgM
CD18, 950, 1083, 1184 CD27, 1172, 1528, 1785, 1788, 2234 with, 1213
CD19 CD27 deficiency, 1220 in myelodysplastic syndromes, 1352
in B cells, 1141 CD28, 415–416, 1183, 1184, 1185f in platelets, 1872–1873
in Burkitt lymphoma, 1674 CD30 CD40 ligand (CD40L, CD154)
in chronic lymphocytic leukemia, 1528, in anaplastic large cell lymphoma, 1698 in atherosclerosis, 2288
1530, 1539 in cutaneous lymphoproliferative in heavy-chain class switching, 1168
in diffuse large B-cell lymphoma, 1627 disorders, 1688, 1689f in hyperimmunoglobulin M syndromes,
in follicular lymphoma, 1642, 1644 in Hodgkin lymphoma, 1599, 1607, 1609, 1213, 1214t
in mantle cell lymphoma, 1653 1610, 1617 in immune thrombocytopenia, 2008
natural killer cell tumor killing and, 1193 in primary effusion lymphoma, 1247 in myelodysplastic syndromes, 1352
in primary mediastinal large B-cell in primary mediastinal large B-cell platelet activation and, 2293
lymphoma, 1634 lymphoma, 1634 in platelets, 1856, 1872–1873
as T-cell therapy target, 415–416 as therapeutic target. See Bortezomib; in red cell transfusion, 2375, 2376
in Waldenström macroglobulinemia, 1785 Brentuximab vedotin structure, 1872
CD20 CD31. See Platelet-endothelial cell adhesion in T cells, 93
in B cells, 1141 molecule-1 (PECAM-1, CD31) CD41/CD61. See Integrin α β
IIb 3
in Burkitt lymphoma, 1674 CD32. See Fcγ receptor IIA (FcγRIIA, CD32) CD42. See Glycoprotein (GP)Ib/IX/V
in chronic lymphocytic leukemia, 1528 CD33 complex (CD42)
in diffuse large B-cell lymphoma, 1627 in acute lymphoblastic leukemia, 1512 CD42a. See Glycoprotein (GP)IX (CD42a)
in extranodal marginal zone lymphoma, in acute myelogenous leukemia, 271, CD42b,c. See Glycoprotein (GP)Ibα
1665 1380t, 1383 (CD42b,c)
in follicular lymphoma, 1576f, 1642, 1645, lymphoid progenitors and, 1154 CD43, 1653, 1873
1647 structure, 1052f CD44
in Hodgkin lymphoma, 1599, 1609, 1610, CD33 antibodies. See Gemtuzumab in B-1 B cells, 1141
1617 ozogamicin chronic myelogenous leukemia and,
leukemia cell expression, 1518 CD34 1440
in mantle cell lymphoma, 1653 in aorta-gonad-mesonephros region, 258 deficiency, 498
in primary mediastinal large B-cell in hematopoietic stem cells, 260 in diffuse large B-cell lymphoma, 1627
lymphoma, 1634 in inflammatory response, 1977 dyserythropoietic anemia and, 568
in pure red cell aplasia, 543 in leukocyte adhesion, 283 hematopoietic stem cell trafficking and,
at target of rituximab, 1141 lymphoid progenitors and, 1153 355
in Waldenström macroglobulinemia, 1785 in stem cell adhesion and homing, 66 in marrow cells, 62, 266–267
CD20+ cells, in Hodgkin lymphoma, 1609 CD34+ cells memory T cells and, 1183
CD20-targeting antibodies. See in acute myelogenous leukemia, 1376 in myeloma, 1737
Obinutuzumab; Ofatumumab; in aplastic anemia, 515, 516f CD45, 1599
Rituximab in chronic myelogenous leukemia, CD45 (T200), 1183, 1247
CD21, 1573, 1665 1444–1445 CD45RA, 1153, 1183
CD22, 1141, 1163, 1555 cultures, 463 CD45RB, 1183
in Burkitt lymphoma, 1674 in hematopoietic cell transplantation, 356 CD45RO, 1183
in diffuse large B-cell lymphoma, 1627 in lymphopoiesis, 1150 CD45RO+ cells, 411, 411f
in follicular lymphoma, 1642, 1647 in myeloma, 1714 CD47, 1845, 1879
in primary mediastinal large B-cell in primary myelofibrosis, 1321, 1326 CD48, 949
lymphoma, 1634 CD35, 1009, 1054, 1665 CD49b/CD29. See Integrin α β
in Waldenström macroglobulinemia, CD36. See Glycoprotein (GP)IV (CD36, FAT, CD49d, 1532, 1532t 2 1
1785 SCARB3) CD49e/CD29. See Integrin α β
5 1

Kaushansky_index_p2393-2506.indd 2411 9/21/15 3:21 PM